SinoNordic LifeCare FundSinoNordic LifeCare Fund
For companies & founders

You did the hard part. The next wall is capital — and Hong Kong.

SinoNordic LifeCare Fund backs validated Nordic life science companies and gives them a structured path into Hong Kong capital and markets.

What we offer

More than a cheque.

We are not a passive cheque. The connection into Hong Kong is the point.

Growth capital

Funding aligned with your stage, from a fund built specifically for cross-border life science.

A built route into Hong Kong

Market entry, regulatory navigation, local partnerships, and commercial and manufacturing scale — the access most companies cannot assemble alone.

The hard parts handled

We carry the cross-border engineering: structuring, IP protection, and governance, so you can keep building.

Who we back

The companies we build for.

  • Nordic life science & healthcare: medtech, biotech, diagnostics, digital health.
  • Past the science risk — a credible clinical or commercial signal, not just a concept.
  • Scale-stage: ready to grow, constrained by capital and/or market reach.
  • Clear Hong Kong relevance: a product a large, ageing, fast-growing market actually needs.
  • Defensible intellectual property.

Not quite there yet? We are still glad to hear from you early.

How it works

From first conversation to scale.

  1. 01

    Conversation

    A confidential first discussion about your company and ambitions.

  2. 02

    Fit & diligence

    We assess the science, the Hong Kong relevance, and the right structure.

  3. 03

    Structure

    We build the vehicle that protects your IP and aligns everyone.

  4. 04

    Capital + access

    Funding paired with a concrete Hong Kong entry plan.

  5. 05

    Scale

    Execution into the Hong Kong market, together.

On IP and confidentiality

Your intellectual property is the company, and we treat it that way. First conversations are held in confidence, and any structure we propose is designed to protect core IP rather than expose it — a non-negotiable for us and for our investors alike.

Intake

Tell us about your company.

A short note is enough to start a conversation. We'll reply personally.

All enquiries are treated as confidential.